Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 68, Issue 8, 2009, Pages 1367-1368

  Bohanec Grabar, P ^a   Rozman, B ^b   Logar, D ^b   Praprotnik, S ^b   Dolzan V ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYTOCHROME P450 1A2; DIHYDROOROTATE DEHYDROGENASE; GENOMIC DNA; LEFLUNOMIDE;

ABDOMINAL PAIN; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; DIARRHEA; DRUG EFFECT; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HUMAN; LETTER; NAIL DISEASE; NAUSEA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE; VAGINITIS; WEIGHT REDUCTION;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYTOCHROME P-450 CYP1A2; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; POLYMORPHISM, GENETIC;

EID: 67651230875     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.099093     Document Type: Letter

References (7)

1. Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Dordevic J, et al. Safety and effectiveness of leflunomide in the treatment of patientswith active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995;38:1595- 603.
2. Kalgutkar AS, Nguyen HT, Vaz AD, Doan A, Dalvie DK, McLeod DG, et al. In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes. Drug Metab Dispos 2003;31:1240-50.
3. Bohanec Grabar P, Rozman B, Tomsic M, Suput D, Logar D, Dolzan V. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur J Clin Pharmacol 2008:64:871-6.
4. Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000;59:841-9.
5. Chonlahan J, Halloran MA, Hammonds A. Leflunomide and warfarin interaction: case report and review of the literature. Pharmacotherapy 2006;26:868-71.
6. Lim V, Pande I. Leflunomide can potentiate the anticoagulant effect of warfarin. BMJ 2002;325:1333.
7. Sevilla-Mantilla C, Ortega L, Agundez JA, Fernandez-Gutierrez B, Ladero JM, Diaz-Rubio M. Leflunomide-induced acute hepatitis. Dig Liver Dis 2004;36:82-4.